Sichuan pharmaceutical companies won more than 10 billion anti-thrombosis drugs!

Pharmaceutical Network December 28th, December 25th, the official website of the State Drug Administration shows that Yuandong Biological's hydrochlorochloropolytic tablets of hydrochloride sulfate were approved for listing in the imitation category 4.
of clopidogrete tablets in china's public medical institutions has exceeded 10 billion yuan in recent years, according to data from The New York Post.
, Sanofi has the largest market share, at 46.74 per cent.
2020H1 China's public medical institutions terminal clopidogrete brand pattern Source: China's public medical institutions terminal competition pattern hydrochlorochlorogre tablets are a platelet aggregation inhibitors, used in ischemia stroke, acute myocardial infarction and so on. In recent years, sales of clopidogre tablets at urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) have exceeded 10 billion yuan, according to
meters of intranet data.
source: MED2.0 China Drug Review Database Hydrochlorocarpide tablets have Sanofi, Xinlitai, Lepu Pharmaceuticals, Stone Pharmaceuticals, Eoi Pharmaceuticals and more than 10 other production enterprises, of which Sanofi has the largest market share, up to 46.74 percent.
notable is that Sanofi's market share has gradually declined, from more than 60% in 2016 to less than 50% in the first half of this year, as domestic pharmaceutical companies have been making rapid efforts.
the evaluation of the consistency of the 10 enterprises, such as Xinlitai, Lepu Pharmaceuticals, Stone Pharmaceuticals, O-Italian Pharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals, etc. have been evaluated.
currently, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, Beijing Four Rings Pharmaceuticals and other enterprises are copying 4 categories of applications submitted for listing in the review and approval (in the drug review center).
。